7:31 AM
 | 
May 08, 2019
 |  BC Extra  |  Company News

Gilead’s Goldfinch deal signals renewed optimism in kidney therapies

Editor's Note: This article was updated on May 08, 2019 at 2:48 PM PDT

In the latest sign of that the kidney is regaining attention for drug developers, Gilead has tapped Goldfinch's drug discovery tools to co-develop therapies for diabetic kidney disease and orphan kidney diseases.

Goldfinch Biopharma Inc. (Cambridge, Mass.) CEO Tony Johnson told BioCentury that after a string of past failures among pharma companies developing kidney therapies, the space is now opening up with a better regulatory environment and greater understanding of kidney disease.

Last year, FDA began allowing proteinuria as a surrogate endpoint for certain kidney diseases such as focal segmental glomerulosclerosis...

Read the full 444 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >